The Master Virus Seed Stock (MVSS) and Working Virus Seed Stock (WVSS) are core starting materials for vaccines, gene therapies, and cell therapies. Their quality directly impacts final product safety, efficacy, and consistency. Common risks in virus seed bank release include genetic instability, replication-competent virus contamination (RCL/RCR/rcAAV), and adventitious virus introduction. If issues are detected after release, re-validation can delay programs by 6 to 12 months.
Based on ICH Q5A(R2), FDA CGT Guidance, and compendial standards, Creative Biogene provides a complete virus seed bank release testing service covering identity, purity, titer, replication-competent virus, adventitious agents, mycoplasma, and sterility – delivered as an IND/BLA-ready data package.
| Project Stage | Recommended Package | Key Inclusions |
| Early R&D / Process development | Rapid Release | Virus identity (targeted sequencing/qPCR), infectious titer (qPCR), purity (SDS-PAGE), mycoplasma (qPCR rapid), sterility. Maximizes timeline compression for iterative testing. |
| Pre-IND / CTA submission | Advanced Release | Identity (WGS), infectious titer (TCID50/plaque assay), purity (SDS-PAGE + TEM empty particle analysis), adventitious virus (in vitro + in vivo), species-specific virus PCR panel, replication-competent virus (RCL/RCR/rcAAV), mycoplasma (culture + qPCR dual), sterility. Fully covers ICH Q5A(R2) requirements. |
| Commercial manufacturing | Core Release | Virus identity (restriction mapping/qPCR), infectious titer (TCID50/plaque assay), basic purity (SDS-PAGE), mycoplasma (qPCR), and sterility. Suitable for established processes and routine release. |
| Testing Item | Core Release | Advanced Release | Rapid Release |
| Virus identity – restriction mapping / qPCR | ✓ | — | ✓ (targeted) |
| Virus identity – whole genome sequencing (WGS) | — | ✓ | — |
| Infectious titer – TCID50 / plaque assay | ✓ | ✓ | — |
| Infectious titer – qPCR method | — | — | ✓ |
| Purity – SDS✓PAGE / HPLC | ✓ | ✓ | ✓ (SDS✓PAGE) |
| Purity – TEM empty particle analysis | — | ✓ | — |
| Adventitious virus – in vitro co-culture | — | ✓ | Simplified |
| Adventitious virus – in vivo animal | — | ✓ | — |
| Species-specific virus – PCR panel | — | ✓ | On request |
| Replication-competent virus – RCL/RCR/rcAAV | — | ✓ | — |
| Mycoplasma – culture (USP <63>) | — | ✓ | — |
| Mycoplasma – qPCR rapid | ✓ | ✓ | ✓ |
| Sterility (USP <71>) | ✓ | ✓ | ✓ |
For specific test panels, method parameters, or a customized proposal with pricing, please contact our technical team.
Drawing on 10+ years of viral platform experience and a GMP system designed for live vectors, Creative Biogene moves beyond checklists. We build each release around risk identification, stage-appropriate strategy design, and IND-ready data.
1. Compliance Framework
Built on ICH Q5A(R2), with GLP and cGMP principles followed. Data management follows ALCOA+ principles, full LIMS traceability, and independent QA review for each batch.
2. Method Validation
Pharmacopoeial methods are qualified for applicability; non-pharmacopoeial methods are validated in parallel with pharmacopoeial methods, and complete validation reports are provided.
3. Platform Integration
We integrate cutting-edge technologies (whole genome sequencing / restriction mapping, ddPCR/qPCR, TCID50/plaque assay, TEM) with traditional methods into a unified technical platform.
4. Submission-Ready Reporting
Reports are designed with IND/BLA submission as the endpoint, including method descriptions, raw data, compliance statements, and expert interpretation – ready for direct inclusion in the virus seed bank section of CMC documentation.
| Platform | Key Equipment / Capability | Description |
| Molecular Biology | qPCR instrument, digital PCR (ddPCR), Sanger sequencer, Illumina NGS | Supports virus identity (WGS), low-abundance RCL/RCR detection, species-specific virus PCR screening, and genetic stability analysis. |
| Virology | BSL-2/BSL-2+ biosafety cabinets, CO- incubators, inverted fluorescence microscope, automated cell imaging system | Supports infectious titer determination (TCID50, plaque assay, PRNT) and in vitro co-culture for adventitious virus detection. |
| Microbiology | Biosafety cabinets, multi-zone incubators (aerobic/anaerobic), automated colony counter | Supports sterility testing (USP <71> membrane filtration/direct inoculation) and mycoplasma culture (USP <63>); automated counting reduces bias. |
| Electron Microscopy | Transmission electron microscope (TEM) | Supports virus particle morphology observation, empty particle count analysis, and purity assessment. |
| Animal Testing | SPF animal facility | Supports in vivo adventitious virus testing, compliant with ICH Q5A requirements. |
| Mass Spectrometry | MALDI-TOF MS | Supports host cell protein residue testing and assists purity analysis. |
Whole genome sequencing or restriction enzyme mapping per ICH Q5A(R2) and FDA CGT Guidance, used for MVSS/WVSS release to confirm strain identity and genetic stability.
TCID50, plaque assay, or qPCR per ICH Q5A(R2) and EP 2.6.8; infectious titer (PFU/mL or TCID50/mL) is reported for virus seed bank release.
SDS-PAGE, HPLC, or TEM (particle counting) following industry practice and ICH Q6B principles, used to detect host cell proteins, DNA, and empty particles.
Culture method plus qPCR (rapid method requires validation) per USP <63> framework; mandatory for virus seed banks.
Membrane filtration or direct inoculation per USP <71>; mandatory for virus seed bank release.
Select the appropriate test based on the vector type.
If you are preparing for GMP release of a virus seed bank or have uncertainties about testing strategy at a critical IND submission node, now is the best time to front-load risks and validate proactively. We will design a systematic testing strategy and method combination tailored to your virus type (AAV/LV/Retro/HSV/AdV, etc.), seed bank level (MVSS/WVSS), and application scenario – ensuring every decision is supported by robust data, increasing certainty and controllability from the virus seed bank source. Contact us today to request your customized virus seed bank release testing plan.
Q1: Is virus seed bank release testing mandatory for an IND submission?
A: Yes. ICH Q5A(R2) explicitly requires a comprehensive viral safety evaluation of virus seed banks, and the FDA strictly reviews virus seed bank testing data during IND review. ICH Q5A(R2) describes the overall framework for viral safety evaluation of biotechnology products, requiring tiered testing of cell substrates, virus seeds, bulk harvests, and final products. The FDA CGT Guidance (2020) also requires full characterization of virus seed banks for viral vector products.
Q2: What are the advantages of whole genome sequencing (WGS) over traditional restriction mapping? Is it necessary?
A: WGS provides single-nucleotide resolution, can detect low-frequency mutations and genetic drift, and is recognized by ICH Q5A(R2) as an advanced method. For GMP seed banks intended for IND submission, WGS is strongly recommended. ICH Q5A(R2) added recognition of molecular biology methods; NGS is now formally accepted as a technical option for adventitious virus detection and genetic stability assessment. Restriction mapping can only confirm the presence or absence of restriction sites, whereas WGS can identify any base-level mutation (including potential loss-of-function mutations). Early research-grade seed banks can use restriction mapping for rapid identity confirmation; for GMP seed banks before IND submission, use WGS directly. NGS can also detect adventitious virus sequences simultaneously, achieving “one test, multiple uses.”
Q3: How should the virus panel for species-specific virus testing be selected?
A: Choose the virus panel based on the production cell line’s history and species origin, covering known viruses that can infect that species. ICH Q5A(R2) Section 3.3 requires species-specific virus testing according to cell origin. For example, BHK cells may carry retroviruses, HEK293 cells may carry adenoviruses, and Sf9 cells are associated with rhabdoviruses. Provide your cell line source information in advance. Our technical team will customize the virus panel based on cell history, species background, and vector system. Testing methods can include PCR, qPCR, or NGS – NGS can cover multiple targets simultaneously and detect unknown viruses.
Q4: Should I choose the culture method or qPCR for mycoplasma detection?
A: Culture is the pharmacopoeial gold standard, but takes 28 days. qPCR can be completed in 1-3 days with comparable sensitivity and is recognized by USP as an alternative method. USP <63> allows either culture or nucleic acid amplification techniques (NAT) for mycoplasma detection. Standard culture requires 28 days to report a negative result, which is incompatible with the short shelf life of CGT products. PCR methods can be completed in days and are recognized by USP as equivalent. For GMP release testing, consider a dual strategy of culture + qPCR. Culture provides the most authoritative result (but with a long lead time); qPCR rapid is suitable for process control and emergency release. For time-sensitive projects, prioritize qPCR and supplement with culture later for confirmation.
Copyright © 2026 Creative Biogene. All rights reserved.